General
Preferred name
SULFINPYRAZONE
Synonyms
(+/-)-Sulfinpyrazone ()
G-28315 ()
NSC 75925 ()
Sulfinpyrazone ()
G-28315, NSC 75925 ()
sufinpyrazone ()
Anturane ()
Anturan ()
NSC-75925 ()
Sulfinpirazona ()
P&D ID
PD001742
CAS
57-96-5
Tags
available
drug
Approved by
FDA
First approval
1959
Drug indication
Gout
Drug Status
approved
withdrawn
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
DESCRIPTION
Sulfinpyrazone (G-28315) is an orally active and potent uricosuric agent for chronic and intermittent gouty arthritis. Sulfinpyrazone has antithrombotic and platelet inhibitory effects[1][2].
DESCRIPTION
Sufinpyrazone is a uricosuric anti-gout medication, i.e. it increases excretion of uric acid in the urine.
(GtoPdb)
DESCRIPTION
Sulfinpyrazone is an oral uricosuric agent (pyrazolone derivative) used to treat chronic or intermittent gouty arthritis. Sulfinpyrazone competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby facilitating urinary excretion of uric acid and decreasing plasma urate concentrations. It also has an agonist effect on fmet-leu-phe receptor.
(Enamine Bioactive Compounds)
DESCRIPTION
Sulfinpyrazone is a uricosuric medication used to treat gout. It inhibits uric acid reabsorption in kidney proximal tubules. It can also used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane. It was developed by Novartis and has been listed.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Sulfinpyrazone (NSC-75925) is a uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
31
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
JUMP-Target 1 Compound Set
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
30
Molecular Weight
404.12
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
3.8
TPSA
57.69
Fraction CSP3
0.13
Chiral centers
1.0
Largest ring
6.0
QED
0.59
Structural alerts
1
keto_keto_beta_B(12)
[#6;X4]-1-[#6](=[#8])-[#7]-[#7]-[#6]-1=[#8]
PAINS Family C
Related compounds
Custom attributes
(extracted from source data)
MOA
organic anion transporter inhibitor
URAT1 Inhibitors
OAT4 Inhibitors
Multidrug resistance-associated protein inhibitors
Target
Solute carrier family 22 member 12
COX
FPR1
Endogenous Metabolite
Member status
member
ATC
M04AB02
Therapeutic Class
Uricosuric Agents
Pathway
Immunology/Inflammation
Neuroscience
Metabolic Enzyme/Protease
Solubility
Soluble in DMSO, not in water
Source data
